Additional cytogenetic features determine outcome in patients allografted for TP53 mutant acute myeloid leukemia

Justin Loke, Myriam Labopin, Charles Craddock, Jan J. Cornelissen, Hélène Labussière-Wallet, Eva Maria Wagner-Drouet, Gwendolyn Van Gorkom, Nicolaas P.M. Schaap, Nicolaus M. Kröger, Joan Hendrik Veelken, Montserrat Rovira, Anne Lise Menard, Gesine Bug, Ali Bazarbachi, Sebastian Giebel, Eolia Brissot, Arnon Nagler, Jordi Esteve, Mohamad Mohty*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

8 Citations (Scopus)
31 Downloads (Pure)


BACKGROUND: The presence of TP53 mutations is associated with an unfavorable outcome in patients allografted for acute myeloid leukemia (AML), leading some to question the benefit of an allogeneic stem cell transplantation (allo-SCT) for this patient group, although this has not been studied in a large cohort. METHODS: A total of 780 patients with AML in first complete remission, with either intermediate- or adverse-risk cytogenetics, whose TP53 mutation status was reported, were included in this study from the European Society for Blood and Marrow Transplantation. RESULTS: Two-year overall survival (OS) was impaired in patients (n = 179) with evidence of a TP53 mutation at diagnosis (35.1%; 95% confidence interval [CI], 26.7–43.7) as compared to the cohort without (n = 601) (64%; 95% CI, 59.1–68.4; P =.001). In patients with mutant TP53 AML with no evidence of either chromosome 17p loss (17p–) and/or complex karyotype (CK) (n = 53, 29.6%), 2-year OS was 65.2% (95% CI, 48.4–77.6). This was not significantly different to patients without TP53 mutations. In patients with mutant TP53 AML with either 17p– and/or CK (n = 126, 70.4%), the OS was lower (24.6%; 95% CI, 16.2–34; P =.001). CONCLUSIONS: In summary, the adverse prognostic effect of TP53 mutations in AML following an allo-SCT is not evident in patients with neither co-occurring 17p– and/or CK, and these data inform decisions regarding allo-SCT in patients with TP53 mutant AML.

Original languageEnglish
Pages (from-to)2922-2931
Number of pages10
Issue number15
Publication statusPublished - 1 Aug 2022

Bibliographical note

This work was supported by research support and clinical trials funding from Cancer Research UK, Cure Leukemia, and Bloodwise.

Publisher Copyright © 2022 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.


Dive into the research topics of 'Additional cytogenetic features determine outcome in patients allografted for TP53 mutant acute myeloid leukemia'. Together they form a unique fingerprint.

Cite this